Carbidopa and Levodopa NDC 16571-158

NDC codes

FDA NDC Directory

Product NDC (as listed)16571-158Labeler and product segments. Claims need a package NDC.

Product NDC at billing width16571-0158Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
16571-158-01	16571015801	100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (16571-158-01)Marketed from Jan 8, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Carbidopa and Levodopa
Generic name (nonproprietary): carbidopa and levodopa
Active ingredients: Carbidopa — 25 mg/1Levodopa — 100 mg/1
Dosage form: Tablet, Orally disintegrating
Route: Oral
Labeler: Rising Pharma Holdings, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 078893
Marketing start: Jan 8, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Aromatic (Chemical structure)
Identifiers: Product ID 16571-158_bf8b1cec-9b24-4102-b948-08c988bfca91SPL ID bf8b1cec-9b24-4102-b948-08c988bfca91SPL set ID 302bfe03-d222-4a87-80ff-f2dbfb9a07f4RxCUI 476399, 476515, 483090UNII 46627O600J, MNX7R8C5VO
Pharmacologic class: Aromatic Amino Acid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N416571015801 followed by a unit qualifier and the quantity

Package 16571-0158-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 27, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Carbidopa and levodopa orally disintegrating tablets are indicated in the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson’s disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on carbidopa and levodopa orally disintegrating tablets. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance th…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 078893

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 078893
Product	Strength	Form · route	Labeler	Product NDC
Carbidopa and Levodopa	Carbidopa 10 mg/1; Levodopa 100 mg/1	Tablet, Orally disintegratingOral	Rising Pharma Holdings, Inc.	16571-157
Carbidopa and Levodopa	Carbidopa 25 mg/1; Levodopa 250 mg/1	Tablet, Orally disintegratingOral	Rising Pharma Holdings, Inc.	16571-159